About ideaya biosciences inc - IDYA
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
IDYA At a Glance
IDEAYA Biosciences, Inc.
5000 Shoreline Court
South San Francisco, California 94080
| Phone | 1-650-443-6209 | Revenue | 218.71M | |
| Industry | Pharmaceuticals: Major | Net Income | -113,698,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 3,024.429% | |
| Fiscal Year-end | 12 / 2026 | Employees | 145 | |
| View SEC Filings |
IDYA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.986 |
| Price to Book Ratio | 2.967 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.819 |
| Enterprise Value to Sales | 11.19 |
| Total Debt to Enterprise Value | 0.011 |
IDYA Efficiency
| Revenue/Employee | 1,508,344.828 |
| Income Per Employee | -784,124.138 |
| Receivables Turnover | 36.616 |
| Total Asset Turnover | 0.196 |
IDYA Liquidity
| Current Ratio | 11.336 |
| Quick Ratio | 11.336 |
| Cash Ratio | 10.871 |
IDYA Profitability
| Gross Margin | 97.90 |
| Operating Margin | -72.842 |
| Pretax Margin | -51.986 |
| Net Margin | -51.986 |
| Return on Assets | -10.182 |
| Return on Equity | -10.922 |
| Return on Total Capital | -10.82 |
| Return on Invested Capital | -10.683 |
IDYA Capital Structure
| Total Debt to Total Equity | 2.729 |
| Total Debt to Total Capital | 2.656 |
| Total Debt to Total Assets | 2.516 |
| Long-Term Debt to Equity | 2.696 |
| Long-Term Debt to Total Capital | 2.624 |